Advances in the early detection of ovarian cancer

Nursing for Women's Health

Volumn 14, Issue 3, 2010, Pages 222-234

  Cesario, Sandra ^a  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ALGORITHM; BLOOD; COMPLICATION; DEGLUTITION DISORDERS; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EPIDEMIOLOGY; FEMALE; HUMAN; IMMUNOASSAY; MASS SCREENING; MORTALITY; NANOTECHNOLOGY; NURSE ATTITUDE; NURSING; OVARIAN NEOPLASMS; PAIN; PATIENT EDUCATION; PROCEDURES; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UNITED STATES; URINATION DISORDERS;

ALGORITHMS; CA-125 ANTIGEN; DEGLUTITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOASSAY; MASS SCREENING; NANOTECHNOLOGY; NURSE'S ROLE; OVARIAN NEOPLASMS; PAIN; PATIENT EDUCATION AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; URINATION DISORDERS;

EID: 77955993277     PISSN: 17514851     EISSN: 1751486X     Source Type: Journal    
DOI: 10.1111/j.1751-486X.2010.01543.x     Document Type: Article

References (36)

1. Cancer facts and figures 2008 2008, American Cancer Society, Atlanta, GA, Author
2. 2009, http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_ovarian_cancer_be_found_early_33.asp?rnav=cri, American Cancer Society, Detailed guide: Ovarian cancer-Can ovarian cancer be found early? Retrieved from
3. ACOG Committee on Gynecologic Practice. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Gynecologic Oncology 2002, 87:237-239. American College of Obstetricians and Gynecologists
4. ACOG Practice Bulletin No. 83: Management of adnexal masses. Obstetrics and Gynecology 2007, 110((1)):201-214. American College of Obstetricians and Gynecologists
5. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstetrics and Gynecology 2009, 113((4)):957-966. American College of Obstetricians and Gynecologists
6. Badgwell D, Bast R. Early detection of ovarian cancer. Disease Markers 2007, 23((5-6)):397-410.
7. Bast R, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J. New tumor markers: CA125 and beyond. International Journal of Gynecologic Cancer 2005, ((Suppl. 3)):274-281.
8. Bast R, Brewer M, Zou C, Hernandez M, Daley M, Ozols R. Prevention and early detection of ovarian cancer: Mission impossible? Recent Results Cancer Research 2007, 174:91-100.
9. Brown P, Palmer C. The preclinical natural history of serous ovarian cancer: Defining the target for early detection. PLoS Medicine 2009, 6((7)).
10. Burgess R. Medical applications of nanoparticles and nanomaterials. Studies in Health Technology and Informatics 2009, 149:257-283.
11. Clarke-Pearson D. Screening for ovarian cancer. New England Journal of Medicine 2009, 361((2)):170-177.
12. Garcia M, Jemal A, Ward E, Center M, Hao Y. Global cancer facts and figures 2007, Atlanta, GA, American Cancer Society
13. Goff B, Mandel L, Drescher C, Urban N, Gough S, Schurman K. Development of an Ovarian Cancer Symptom Index: Possibilities for earlier detection. Cancer 2007, 109((2)):221-227.
14. Goff B, Mandel L, Melancon C, Muntz H. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. Journal of the American Medical Association 2004, 291((22)):2705-2712.
15. Havrilesky L, Sanders G, Kulasingam S, Myers E. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecologic Oncology 2008, 111((2)):179-187.
16. Horvath G, Jarverud G, Jarverud S, Horvath I. Human ovarian carcinomas detected by specific odor. Integrative Cancer Therapies 2008, 7((2)):76-80.
17. Jemal A, Thun M, Ries L, Howe H, Weir H, Center M. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. Journal of the National Cancer Institute 2008, 100:1672-1694.
18. McLemore M, Miaskowski C, Aouizerat B, Chen L, Dodd M. Rules of tumor cell development and their application to biomarkers for ovarian cancer. Oncology Nursing Forum 2008, 35((3)):403-409.
19. McLemore M, Miaskowski C, Aouizerat B, Chen L, Dodd M. Epidemiological and genetic factors associated with ovarian cancer. Cancer Nursing 2009, 32((4)):281-288.
20. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology 2009, 10:327-340.
21. Mills P, Riordan D, Cress R, Young H. Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California. International Journal of Cancer 2004, 112((3)):458-464.
22. Nan M, Sargent E, Kelley S. One-step DNA-programmed growth of luminescent and biofunctionalized nanocrystals. Nature nanotechnology 2009, 4((2)):121-125.
23. 2009, http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf, National Comprehensive Cancer Network, NCCN Practice Guidelines in Oncology: ovarian cancer and genetic screening. Retrieved from
24. Nelson A, Francis J, Zorbas H. Population screening and early detection of ovarian cancer in asymptomatic women. Australian and New Zealand Journal of Obstetrics and Gynaecology 2009, 49((5)):448-450.
25. Nosov V, Su F, Amnerus M, Bierrer M, Robins T, Kotlerman J. Validation of serum biomarkers for detection of early-stage ovarian cancer. American Journal of Obstetrics and Gynecology 2009, 200:639 e1-639 e5.
26. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman E W. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences 2007, 104:12837-12842.
27. Partridge E, Kreimer A, Greenlee R, Williams C, Xu J. Results from four rounds of ovarian cancer screening in a randomized trial. Obstetrics and Gynecology 2009, 113((4)):772-774. PLCO Project Team
28. Rosen D, Wang L, Atkinson J, Yu Y, Lu Y, Diamandis E. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology 2005, 99((2)):267-277.
29. Ryerson A, Eheman C, Burton J, McCall N, Blackman D, Subramanian S. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstetrics and Gynecology 2007, 109((5)):1053-1061.
30. Smith L, Morris C, Yasmeen S, Parikh-Patel A, Cress R, Romano P. Ovarian cancer: Can we make the clinical diagnosis earlier? Cancer 2005, 104:1398-1407.
31. Song H, Ramus S, Tyrer J, Bolton K, Gentry-Maharaj A, Wozniak E. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics 2009, 41:996-1000.
32. Trivers K, Stewart S, Peipins L, Rim S, White M. Expanding the public health research agenda for ovarian cancer. Journal of Women's Health 2009, 18((9)):1299-1305.
33. Screening for ovarian cancer: Recommendation statement. American Family Physician 2005, 71:759-762. U.S. Preventive Services Task Force
34. Vergote I, Amant F, Ameye L, Timmerman D. Screening for ovarian carcinoma: Not quite there yet. Lancet Oncology 2009, 10((4)):308-309.
35. Visintin I, Feng Z, Longton G, Ward D, Alvero A, Lai Y. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research 2008, 14((4)):1065-1072.
36. Webb P, Purdie D, Grover S, Jordan S, Dick M, Green A. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecologic Oncology 2004, 92((1)):232-239.